share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股SEC公告 ·  09/30 08:03

Moomoo AI 已提取核心訊息

On September 30, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which began on February 6, 2024, aims to buy back shares worth up to DKK 20 billion over a 12-month period. As part of this initiative, a specific tranche was initiated on August 7, 2024, with the intention to repurchase up to DKK 2.4 billion in B shares by November 4, 2024. Since the last announcement on September 23, 2024, Novo Nordisk has purchased an additional 205,935 B shares at an average price of DKK 835.48, amounting to DKK 172,706,664. This brings the total repurchased under the program to 1,604,058 B shares at an average price of DKK 880.84, totaling DKK 11,161,264,179. The company now holds 13,999,815 B shares as treasury shares, representing 0.3% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.
On September 30, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which began on February 6, 2024, aims to buy back shares worth up to DKK 20 billion over a 12-month period. As part of this initiative, a specific tranche was initiated on August 7, 2024, with the intention to repurchase up to DKK 2.4 billion in B shares by November 4, 2024. Since the last announcement on September 23, 2024, Novo Nordisk has purchased an additional 205,935 B shares at an average price of DKK 835.48, amounting to DKK 172,706,664. This brings the total repurchased under the program to 1,604,058 B shares at an average price of DKK 880.84, totaling DKK 11,161,264,179. The company now holds 13,999,815 B shares as treasury shares, representing 0.3% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.
2024年9月30日，全球領先的醫療保健公司諾和諾德報告了其股份回購計劃的進展。該計劃始於2024年2月6日，旨在在12個月內回購價值多達200億丹麥克朗的股份。作爲此舉的一部分，一個具體的 tranche 於2024年8月7日啓動，計劃到2024年11月4日之前回購價值多達24億丹麥克朗的 b 類股份。自2024年9月23日最後一次公告以來，諾和諾德以平均每股835.48丹麥克朗的價格又購入了2059350億股，金額爲172,706,664丹麥克朗。這將該計劃下的總回購量提高到16040580億股，平均價格爲880.84丹麥克朗，總額爲111,612,641,179丹麥克朗。公司目前持有139998150億股作爲庫藏股，佔股本的0.3%。成立於1923年並總部位於丹麥的諾和諾德致力於抗擊嚴重慢性疾病，並在全球約僱用着約69,000名員工。
2024年9月30日，全球領先的醫療保健公司諾和諾德報告了其股份回購計劃的進展。該計劃始於2024年2月6日，旨在在12個月內回購價值多達200億丹麥克朗的股份。作爲此舉的一部分，一個具體的 tranche 於2024年8月7日啓動，計劃到2024年11月4日之前回購價值多達24億丹麥克朗的 b 類股份。自2024年9月23日最後一次公告以來，諾和諾德以平均每股835.48丹麥克朗的價格又購入了2059350億股，金額爲172,706,664丹麥克朗。這將該計劃下的總回購量提高到16040580億股，平均價格爲880.84丹麥克朗，總額爲111,612,641,179丹麥克朗。公司目前持有139998150億股作爲庫藏股，佔股本的0.3%。成立於1923年並總部位於丹麥的諾和諾德致力於抗擊嚴重慢性疾病，並在全球約僱用着約69,000名員工。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間